Vaccination of patients with cutaneous melanoma with telomerase-specific peptides

Hunger, Robert E; Kernland Lang, Kristin; Markowski, Carrie J; Trachsel, Sissel; Møller, Mona; Eriksen, Jon A; Rasmussen, Anne-Marie; Braathen, Lasse R; Gaudernack, Gustav (2011). Vaccination of patients with cutaneous melanoma with telomerase-specific peptides. Cancer immunology, immunotherapy, 60(11), pp. 1553-64. Heidelberg: Springer-Verlag 10.1007/s00262-011-1061-z

[img]
Preview
Text
262_2011_Article_1061.pdf - Published Version
Available under License Publisher holds Copyright.

Download (2MB) | Preview

A phase I study was conducted to investigate the safety, tolerability, and immunological responses to vaccination with a combination of telomerase-derived peptides GV1001 (hTERT: 611-626) and p540 (hTERT: 540-548) using granulocyte-macrophage colony-stimulating factor (GM-CSF) or tuberculin as adjuvant in patients with cutaneous melanoma.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Hunger, Robert

ISSN:

0340-7004

Publisher:

Springer-Verlag

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:21

Last Modified:

26 Jun 2018 14:11

Publisher DOI:

10.1007/s00262-011-1061-z

PubMed ID:

21681371

Web of Science ID:

000296084700004

BORIS DOI:

10.7892/boris.7070

URI:

https://boris.unibe.ch/id/eprint/7070 (FactScience: 212220)

Actions (login required)

Edit item Edit item
Provide Feedback